Wanbury Limited
NSE: WANBURY BSE: WANBURY
NSE
301.35
14.35 (5.00%)
Prev Close
287
Open Price
292.9
Volume
142,024
Today Low / High
283.25 / 301.35
52 WK Low / High
154.01 / 329.7
Range
286 - 316
BSE
301.85
14.35 (4.99%)
Prev Close
287.5
Open Price
295
Volume
42,989
Today Low / High
283.5 / 301.85
52 WK Low / High
155 / 330
Range
287 - 317
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 301.35 (target range: 286 - 316), reflecting a change of 14.35 (5%). On the BSE, it is listed at 301.85 (target range: 287 - 317), showing a change of 14.35 (4.9913%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
22 Aug
292.90
2.88%
21 Aug
285.95
0.37%
20 Aug
269.05
4.18%
19 Aug
264.50
3.25%
18 Aug
258.00
0.81%
14 Aug
249.00
1.18%
13 Aug
251.00
-0.66%
12 Aug
254.50
-0.45%
11 Aug
261.85
-4.39%
08 Aug
255.40
-0.06%
07 Aug
259.70
-1.68%
06 Aug
266.30
-4.24%
05 Aug
276.00
-3.68%
04 Aug
268.45
1.43%
01 Aug
266.00
0.92%
31 Jul
256.10
5.00%
30 Jul
253.30
4.56%
29 Jul
242.85
3.87%
28 Jul
245.50
-2.14%
Wanbury Limited Graph
Wanbury Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Wanbury Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 301.35, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 301.85 | 304.87 | 274.38 - 335.36 |
| 307.89 | 246.31 - 369.46 | ||
| 310.91 | 217.63 - 404.18 | ||
| Bearish Scenario | 301.85 | 298.83 | 268.95 - 328.71 |
| 295.81 | 236.65 - 354.98 | ||
| 292.79 | 204.96 - 380.63 |
Overview of Wanbury Limited
ISIN
INE107F01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
54,663
Market Cap
9,907,483,950
Last Dividend
0
Official Website
IPO Date
2007-01-29
DCF Diff
302.49
DCF
-1
Financial Ratios Every Investor Needs
Stock Dividend of WANBURY
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2010-07-29 | July 29, 10 | 1 | 1 | 2010-07-31 | 2010-08-12 | 2010-05-28 |
| 2009-03-12 | March 12, 09 | 0.5 | 0.5 | 2009-03-16 | 2009-03-23 | 2008-12-31 |
| 2007-09-13 | September 13, 07 | 2 | 2 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 599.51 Cr | 294.48 Cr | 305.04 Cr | 0.5088 | 0.00 Cr | 0.00 Cr | 63.00 Cr | 30.53 Cr | 9.32 | 79.81 Cr | 0.0509 |
| 2024-03-31 | 574.48 Cr | 309.18 Cr | 265.30 Cr | 0.4618 | 0.00 Cr | 17.05 Cr | 57.21 Cr | 55.96 Cr | 17.10 | 98.55 Cr | 0.0974 |
| 2023-03-31 | 498.18 Cr | 309.02 Cr | 189.15 Cr | 0.3797 | 0.00 Cr | 13.24 Cr | 11.86 Cr | -10.40 Cr | -3.18 | 23.49 Cr | -0.0209 |
| 2022-03-31 | 507.24 Cr | 307.36 Cr | 199.87 Cr | 0.3940 | 0.00 Cr | 12.46 Cr | 29.78 Cr | 81.47 Cr | 25.29 | 113.19 Cr | 0.1606 |
| 2021-03-31 | 387.10 Cr | 226.21 Cr | 160.89 Cr | 0.4156 | 0.00 Cr | 14.21 Cr | 14.73 Cr | -12.61 Cr | -5.04 | 20.42 Cr | -0.0326 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.06 Cr | 413.92 Cr | 354.65 Cr | 59.2718 Cr | 176.91 Cr | 172.85 Cr | 37.68 Cr | 205.76 Cr | 0.00 Cr | 0.00 Cr | 4.06 Cr | 174.6120 Cr |
| 2024-03-31 | 3.40 Cr | 343.49 Cr | 315.55 Cr | 27.9414 Cr | 116.48 Cr | 113.08 Cr | 36.02 Cr | 169.56 Cr | 0.00 Cr | 0.00 Cr | 0.81 Cr | 214.1057 Cr |
| 2023-03-31 | 1.49 Cr | 303.52 Cr | 336.34 Cr | -6.1542 Cr | 108.58 Cr | 107.09 Cr | 21.99 Cr | 169.93 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 320.0262 Cr |
| 2022-03-31 | 22.53 Cr | 352.55 Cr | 375.97 Cr | -23.4198 Cr | 107.66 Cr | 85.14 Cr | 49.73 Cr | 169.36 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 359.7727 Cr |
| 2021-03-31 | 10.00 Cr | 289.18 Cr | 445.42 Cr | -156.2436 Cr | 203.81 Cr | 193.81 Cr | 24.85 Cr | 178.17 Cr | 3.33 Cr | 0.00 Cr | -0.12 Cr | 355.3544 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 26.1016 Cr | -51.1744 Cr | 25.7332 Cr | -22.9259 Cr | 0.6604 Cr | 4.0605 Cr | -49.0275 Cr | 30.5301 Cr | 63.8240 Cr | 0.0000 Cr | -1.6565 Cr |
| 2024-03-31 | 3.9782 Cr | -16.6254 Cr | 14.5531 Cr | -13.4452 Cr | 1.9059 Cr | 3.4002 Cr | -17.4234 Cr | 55.9563 Cr | 46.3581 Cr | 0.0000 Cr | -14.0358 Cr |
| 2023-03-31 | 19.7972 Cr | -8.8377 Cr | -31.9914 Cr | 7.1691 Cr | -21.0319 Cr | 1.4943 Cr | -12.6281 Cr | -10.2868 Cr | -12.4890 Cr | 0.0000 Cr | 27.7418 Cr |
| 2022-03-31 | 40.5229 Cr | 0.5865 Cr | -28.5846 Cr | 30.8652 Cr | 12.5250 Cr | 22.5262 Cr | -9.6577 Cr | 81.1277 Cr | -60.9389 Cr | 0.0000 Cr | -24.8763 Cr |
| 2021-03-31 | 16.6815 Cr | 8.0441 Cr | -17.3854 Cr | 12.2535 Cr | 7.3402 Cr | 10.0012 Cr | -4.4280 Cr | -12.4057 Cr | -10.4281 Cr | 0.0000 Cr | -12.5955 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 163.18 Cr | 75.35 Cr | 87.84 Cr | 0.5383 | 20.80 Cr | 13.49 Cr | 4.12 | 24.79 Cr | 0.0827 |
| 2025-03-31 | 172.00 Cr | 84.33 Cr | 87.67 Cr | 0.5097 | 26.25 Cr | 20.26 Cr | 6.18 | 31.47 Cr | 0.1178 |
| 2024-12-31 | 133.45 Cr | 61.88 Cr | 71.58 Cr | 0.5363 | 10.62 Cr | 1.22 Cr | 0.38 | 14.78 Cr | 0.0091 |
| 2024-09-30 | 161.19 Cr | 82.02 Cr | 79.17 Cr | 0.4912 | 16.68 Cr | 8.02 Cr | 2.44 | 21.64 Cr | 0.0497 |
| 2024-06-30 | 131.11 Cr | 94.70 Cr | 36.41 Cr | 0.2777 | 7.69 Cr | 1.04 Cr | 0.32 | 11.92 Cr | 0.0079 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.06 Cr | 11.00 Cr | 15.06 Cr | 114.16 Cr | 37.68 Cr | 193.44 Cr | 205.76 Cr | 413.92 Cr | 354.65 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 11.75 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -38.75 Cr |
| 2024-09-30 | 5.89 Cr | 7.86 Cr | 13.76 Cr | 111.49 Cr | 37.63 Cr | 189.64 Cr | 180.89 Cr | 396.78 Cr | 358.03 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 5.90 Cr | 0.00 Cr | 0.00 Cr | 5.90 Cr | 0.00 Cr | 0.00 Cr | -27.94 Cr |
| 2024-03-31 | 3.40 Cr | 2.50 Cr | 5.90 Cr | 89.44 Cr | 36.02 Cr | 159.29 Cr | 170.38 Cr | 343.49 Cr | 315.55 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 20.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 1.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 8.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 33.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,641.80 | ₹3,939,137,904,000.00 | ₹2,098,280.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,151.50 | ₹1,633,032,553,500.00 | ₹681,521.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,685.30 | ₹1,247,271,358,500.00 | ₹279,863.00 |
| Mankind Pharma Limited | MANKIND | ₹2,606.80 | ₹1,075,901,331,568.00 | ₹731,305.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,277.60 | ₹1,063,387,459,020.00 | ₹1,229,762.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.80 | ₹994,960,224,000.00 | ₹307,413.00 |
| Lupin Limited | LUPIN | ₹1,974.70 | ₹901,938,300,900.00 | ₹380,522.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,426.00 | ₹648,759,690,000.00 | ₹99,581.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.40 | ₹610,074,420,800.00 | ₹1,872,840.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,937.30 | ₹546,707,997,300.00 | ₹466,930.00 |
| Laurus Labs Limited | LAURUSLABS | ₹879.10 | ₹474,560,157,500.00 | ₹1,548,001.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,418.40 | ₹359,853,753,600.00 | ₹437,395.00 |
| Cohance Lifesciences Limited | COHANCE | ₹884.70 | ₹338,457,031,978.00 | ₹105,334.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,638.50 | ₹329,643,636,000.00 | ₹49,045.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,747.90 | ₹273,268,433,900.00 | ₹250,994.00 |
| Piramal Enterprises Limited | PEL | ₹1,167.70 | ₹264,691,900,600.00 | ₹183,898.00 |
| Eris Lifesciences Limited | ERIS | ₹1,768.70 | ₹240,909,320,900.00 | ₹37,828.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,479.40 | ₹240,371,432,600.00 | ₹246,819.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,433.00 | ₹210,825,000,000.00 | ₹11,150.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹974.60 | ₹191,570,299,800.00 | ₹29,498.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,888.00 | ₹178,181,651,200.00 | ₹28,474.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,083.00 | ₹172,501,323,000.00 | ₹140,398.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,168.10 | ₹164,800,966,770.00 | ₹172,510.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹882.45 | ₹158,055,619,500.00 | ₹259,072.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹458.50 | ₹111,252,274,000.00 | ₹945,550.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,581.50 | ₹109,248,951,100.00 | ₹46,177.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹851.90 | ₹83,308,067,710.00 | ₹36,218.00 |
| Strides Pharma Science Limited | STAR | ₹865.50 | ₹79,775,471,850.00 | ₹92,326.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹863.25 | ₹78,240,335,715.00 | ₹294,141.00 |
| FDC Limited | FDC | ₹474.65 | ₹77,277,766,500.00 | ₹198,253.00 |
| Innova Captab Limited | INNOVACAP | ₹911.35 | ₹52,151,939,956.00 | ₹70,484.00 |
| Suven Life Sciences Limited | SUVEN | ₹230.75 | ₹50,320,575,500.00 | ₹56,095.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹146.08 | ₹47,406,173,760.00 | ₹195,028.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹483.05 | ₹44,087,973,500.00 | ₹160,106.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.85 | ₹44,021,409,750.00 | ₹240,104.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.20 | ₹39,165,289,020.00 | ₹31,316.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,358.20 | ₹39,002,269,800.00 | ₹5,512.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹363.25 | ₹36,425,983,500.00 | ₹39,528.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹502.80 | ₹35,400,036,240.00 | ₹9,585.00 |
| Hikal Limited | HIKAL | ₹254.90 | ₹31,429,424,900.00 | ₹3,140,867.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹631.60 | ₹30,413,434,800.00 | ₹53,855.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.82 | ₹28,419,284,140.00 | ₹848,541.00 |
| Alembic Limited | ALEMBICLTD | ₹105.52 | ₹27,095,636,534.00 | ₹249,022.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.03 | ₹26,866,184,620.00 | ₹2,369,065.00 |
| Indoco Remedies Limited | INDOCO | ₹279.55 | ₹25,787,900,445.00 | ₹12,570.00 |
Key Executives
Vice Chairman
Mr. Krishnamoorthy Chandran
Gender: male
Year Born: 1958
Chief Financial Officer
Mr. Vinod R. Verma
Gender: male
Year Born:
Chief Executive Officer of India Formulation Business
Mr. Pradeep Patni
Gender: male
Year Born: 1960
Head of API Business
Mr. Prakash Venkataraman B.E., MBA
Gender: male
Year Born: 1966
Compliance Officer & Company Secretary
Mr. Jitendra Jayantilal Gandhi
Gender: male
Year Born:
Whole Time Director
Mr. Mohan Kumar Rayana
Gender: male
Year Born:
Senior Vice President of QA,QC & RA
Mr. Nanasaheb Gunjal
Gender: male
Year Born: 1963
President of Operations - API Business
Dr. Shireesh Bhalchandra Ambhaikar
Gender: Not Specified
Year Born:
FAQs about Wanbury Limited
Who is the CEO of the company?
The CEO is Pradeep Patni.
What is the current market price of the stock?
The current price is ₹301.35.
What is the 52-week price range?
The range is ₹154.01-329.7.
What is the market capitalization of the company?
The market capitalization is ₹990.75 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 22.96.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Wanbury Limited (ISIN: INE107F01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹990.75 crores and an average daily volume of 54,663 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.